Life sciences startups have always been on a mission to improve human health through innovation. The global impacts of the COVID-19 crisis have made the importance of that work clearer than ever. Whether its work directly relates to virus relief efforts or not, every startup in this industry has felt the impact of the crisis. And for startup leaders looking toward the future, it’s important to understand how funding plans could change. 

Peter Meath, Co-Head of Healthcare & Life Sciences for J.P. Morgan Commercial Banking, notes that the pandemic has drawn attention to the space, thereby creating an enormous tailwind of opportunity. And this isn’t just contained to companies focusing on COVID-19—it’s across the board. The public is increasingly recognizing the novel innovation generated by life sciences startups, and investors have a renewed desire to deploy capital in the space.

Click here to read the full article.

Photo: Pixtum, Getty Images

Source link


Please enter your comment!
Please enter your name here